Cure8 research brief
The study documents substantial increases in Crohn’s disease and ulcerative colitis prevalence and changing incidence patterns in Northeastern Italy from 2012–2024, which may affect healthcare demand and resource planning for people with IBD in the region.
Clinicians, health system planners, researchers in IBD epidemiology, and people living with IBD (especially in Northeastern Italy or similar healthcare settings).
Researchers used linked hospital discharge records and healthcare exemption registries to identify IBD cases by ICD-9-CM diagnosis codes and calculated annual point prevalence (2012–2024) and incidence (2013–2024). They found 29,388 prevalent cases (9,656 Crohn’s disease; 18,375 ulcerative colitis) and 14,737 incident cases over the study period.
Crohn’s disease prevalence increased by about 76% (from 0.95 to 1.67 per 1,000) with steady annual rises; ulcerative colitis prevalence increased by about 58% (from 1.97 to 3.11 per 1,000) with decelerating phases. Incidence trends differed: Crohn’s disease rose steadily, while ulcerative colitis showed biphasic dynamics with acceleration after 2020.
The authors note male predominance and aging cohorts.
Based on the article abstract (observational, registry-based study). ICD-9-CM code-based case identification and registry data are useful for population trends but do not capture disease severity, treatments, or causal factors.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest Edoardo Vincenzo Savarino has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, MayolyBiohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, Unifarco; has served as a consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, DiademaFarmaceutici, Dr Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlè, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, Zeta Farmaceutici. Fabiana Zingone has served as a speaker for EG Stada Group, Fresenius Kabi, Janssen, Pfizer, Takeda, Unifarco, Malesci, and Kedrion and has served as a consultant for Galapagos. Luisa Bertin has served as a speaker for Takeda and Edra Spa. The other authors declare that there is no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This large, population-level analysis summarizes long-term global trends in IBD burden and shows rising incidence and persistent geographic and socio-demographic inequalities. Patients and clinicians may see why...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
